Managing AML at Every Stage
Chapter 1: Pretest
To continue, select another chapter from the Chapter List
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
This activity will address several practice-related issues regarding the management of patients with acute myeloid leukemia. Nurses who provide direct patient care may encounter many different hematologic malignancies throughout their day. Consequently, they may face the challenge of remaining current on treatment and monitoring approaches for acute myeloid leukemia at all stages of the disease, from the newly diagnosed patient to the relapsed/refractory patient. Nurses must also understand key needs of younger and older patients. In this text-based activity, four expert faulty provide the background and insights needed to properly manage patients with AML.
This activity is designed for nurses in the community setting who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Describe clinical needs resulting from current standards of care in newly diagnosed AML
- Define the term “elderly” as it relates to AML therapy, focusing on who, when, and how elderly patients with AML should be treated
- Describe the clinical considerations and challenges associated with the care of patients with relapsed/refractory AML
- Outline the efficacy and safety data supporting novel agents for AML currently in clinical development
Novel Therapeutic Approaches in Newly Diagnosed Younger Patients with AML – Pinkal Desai, MD, MPH
Optimizing Treatment in the Older Patient with AML – Farhad Ravandi, MD
Emerging Approaches to Relapsed/Refractory AML – Alexander Perl, MD
The Expanding Landscape: Promising Novel Agents in Clinical Trials – Daniel A. Pollyea, MD
Instructions for Participation and Credit
This activity is eligible for credit through April 26, 2020. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CNE may be printed immediately after successfully completing the post-test and activity evaluation.
Pinkal Desai, MD, MPH
Assistant Professor of Medicine
Weill Cornell Medical College
Assistant Attending Physician
New York-Presbyterian Hospital
New York, New York
Dr. Pinkal Desai received her MBBS at Byram Jeejeebhoy Medical College in India, and her MPH at the University of Alabama at Birmingham School of Public Health. Following her residency at Wayne State University, Detroit Medical Center, she underwent fellowship training in hematology-medical oncology at Providence Hospital Medical Center, serving as chief fellow. Dr. Desai is an Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at the New York-Presbyterian Hospital. She was recruited to serve in the Leukemia Program to develop a clinical practice devoted to leukemia, myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN) where she will also develop the clinical and translational research protocols and projects.
Dr. Desai is a member of the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has served on the ASCO University Committee. She has been published in Cancer Epidemiology Biomarkers Prevention and International Journal of Molecular Epidemiology and Genetics. In addition, Dr. Desai is the lead author and co-author on numerous Women’s Health Initiative (WHI) paper proposals and has presented abstracts at national meetings.
Alexander Perl, MD
Associate Professor of Medicine
Abramson Cancer Center
University of Pennsylvania
Dr. Alexander Perl is a member of the leukemia program at the Abramson Cancer Center of the University of Pennsylvania, where he is an Associate Professor of Medicine. His particular expertise is in FLT3 inhibition as a therapeutic strategy for acute myeloid leukemia, clinical trials, and mechanisms of resistance to tyrosine kinase inhibitors.
Daniel A. Pollyea, MD
Clinical Director of Leukemia Services
Associate Professor of Medicine
Division of Hematology
University of Colorado
Dr. Daniel Pollyea completed his medical training at the University of Chicago Pritzker School of Medicine and his residency training in internal medicine at the University of Chicago Hospitals. He served as Chief Medical Resident at Chicago’s Cook County Hospital and then went to Stanford University for his fellowship training in hematology and oncology, where he also earned a master’s degree in epidemiology. He is now an Associate Professor of Medicine at the University of Colorado in the Division of Hematology, where he also serves as the Clinical Director of Leukemia Services.
Dr. Pollyea’s research interests involve understanding the nature of leukemia stem cells, and finding ways to target them in clinical trials with novel therapies. He serves as principal investigator of multiple clinical trials, has received grant funding from the Leukemia and Lymphoma Society, and has published more than 60 peer-reviewed journal articles.
Farhad Ravandi, MD
Professor, Department of Leukemia
Division of Cancer Medicine
Chief, Section of Developmental Therapeutics
The University of Texas MD Anderson Cancer Center
Dr. Farhad Ravandi received his medical degree from St. Mary's Hospital Medical School/Imperial College, University of London. He completed clinical residencies in internal medicine at The University of Texas, and in hematology at Baylor College of Medicine. He also completed a clinical fellowship in hematology/oncology, and a fellowship in blood and marrow transplantation, hematology/stem cell transplantation at The University of Texas MD Anderson Cancer Center. Dr. Ravandi is a Professor in the Department of Leukemia, Division of Cancer Medicine, and Chief, Section of Developmental Therapeutics at The University of Texas MD Anderson Cancer Center.
Dr. Ravandi holds board certification in internal medicine, medical oncology, and hematology. He is a member of the Southwest Oncology Group Leukemia Committee, the NCCN Acute Myeloid Leukemia Committee, the International Hairy Cell Leukemia Consortium, and the Cancer and Leukemia Group B Data Safety Monitoring Board. Dr. Ravandi is actively involved in clinical and translational research for the treatment of patients with various hematologic malignancies, in particular leukemias. He has extensively published his clinical research results in the field of adult leukemias, with a focus on acute leukemias in numerous peer-reviewed publications, articles, editorials, abstracts, and books/book chapters.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals.
©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 19-013-104
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Pinkal Desai has received honoraria related to formal advisory activities from Agios, argenx, and Cellerant Therapeutics, Inc., as well as consultant fees from Cellerant.
Dr. Alexander Perl has received honoraria as a consultant from Arog Pharmaceuticals, Inc., Asana BioSciences, LLC., Astellas Pharma US, Inc., Daiichi Sankyo, Inc., Novartis AG, and NewLink Genetics Corporation.
Dr. Daniel Pollyea has received honoraria as a consultant from AbbVie Inc., Agios, argenx, Astellas Pharma US, Inc., Celgene Corporation, Celyad, Gilead, and Pfizer Inc. He has received grant support related to research activities from AbbVie Inc. and Pfizer Inc.
Dr. Farhad Ravandi has received honoraria related to formal advisory activities and grant support related to research activities from Amgen Inc., Seattle Genetics, Inc., Sunesis Pharmaceuticals, Inc., and Xencor, in addition to grant support related to research activities from Bristol-Myers Squibb Company and Selvita.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
- Chapter 1: Pretest
- Chapter 2: Novel Therapeutic Approaches in Newly Diagnosed Younger Patients with AML
- Chapter 3: Optimizing Treatment in the Older Patient with AML
- Chapter 4: Emerging Approaches to Relapsed/Refractory AML
- Chapter 5: The Expanding Landscape: Promising Novel Agents in Clinical Trials
- Assessment and Evaluation